VICTORIA, British Columbia, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, is pleased to announce the successful closing of its previously announced public offering (the "Offering") of 7,607,145 common shares of the Company (the “Common Shares"), whi ...

EyePoint (EYPT) shares soared 15.2% in the last trading session to close at $14.91. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 14.2% loss over the past four weeks.EyePoint Pharmaceuticals’ pricesurge is likely tied to the company’s positive developments surrounding its lead candidate, Duravyu. Investor enthusiasm was driven by encouraging clinical progress, particularly around late-stage trial safety and advancement mileston ...

Arquitos Capital Partners, an investment management firm, released its Q4 2025 investor letter. A copy of the letter can be downloaded here. Arquitos Capital Management reported a standout year in which the fund returned 82.1% net of fees in 2025, significantly outperforming the Russell 2000’s 12.8% gain. The manager noted that market conditions became increasingly selective, with capital favoring established, cash-generating businesses while smaller and less liquid growth names faced volatility, particular ...

ALISO VIEJO, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma”), a late-stage biopharmaceutical company, today announced the closing of its initial public offering of 10,781,250 shares of its common stock, which includes the exercise in full of the underwriters’ option to purchase 1,406,250 additional shares of its common stock, at a public offering price of $16.00 per share. The aggregate gross proceeds from the offering were $172.5 million, before deducting u ...

Company Overview - SpyGlass Pharma, Inc. is a late-stage biopharmaceutical company focused on transforming treatment for patients with chronic eye conditions through long-acting, sustained drug delivery of approved medicines [5] - The company was founded in 2019 by Malik Y. Kahook, M.D. and Glenn Sussman to address the lack of ophthalmic innovations that utilize durable treatment options [7] Initial Public Offering (IPO) Details - SpyGlass Pharma announced the pricing of its initial public offering of 9,375,000 shares at a public offering price of $16.00 per share, aiming for aggregate gross proceeds of approximately $150 million [1] - The underwriters have a 30-day option to purchase up to an additional 1,406,250 shares at the initial public offering price [1] - The common stock is expected to begin trading on the Nasdaq Global Select Market under the ticker symbol "SGP" on February 6, 2026, with the offering expected to close on February 9, 2026 [1] Underwriters and Regulatory Information - Jefferies, Leerink Partners, Citigroup, and Stifel are acting as joint book-running managers for the offering [2] - A registration statement for the offering was filed with the Securities and Exchange Commission and became effective on January 30, 2026 [3]

Core Insights - Halozyme Therapeutics has raised its revenue estimates for 2025 and provided updated financial guidance for 2026, reflecting strong growth in its core ENHANZE business and recent acquisitions [1] Financial Estimates for 2025 - Total revenue is estimated to be between $1,385 million and $1,400 million, representing a year-over-year growth of 36% to 38% [1] - Royalty revenue is projected to be between $865 million and $870 million, with a year-over-year growth of 51% to 52% [1] Financial Guidance for 2026 - Total revenue guidance has been increased to a range of $1,710 million to $1,810 million, indicating a year-over-year growth of 23% to 30% [1] - Royalty revenue guidance has been raised to between $1,130 million and $1,170 million, reflecting a growth of 30% to 35% compared to 2025 [1] - Adjusted EBITDA is expected to be between $1,125 million and $1,205 million [1] - Non-GAAP diluted EPS is projected to be between $7.75 and $8.25 [1] Strategic Acquisitions - The company acquired Surf Bio for an upfront payment of $300 million, with potential milestone payments of up to $100 million, totaling up to $400 million [1] - Surf Bio's hyperconcentration technology aims to enable high concentrations of therapeutics for subcutaneous delivery, enhancing patient experience [1] Business Development and Partnerships - In 2025, Halozyme signed three new ENHANZE collaboration and licensing agreements, along with one new auto-injector commercial licensing agreement and two development agreements [1] - The company anticipates having 15 partner programs in development by the end of 2026, further expanding its drug delivery portfolio [1]

Core Insights - Halozyme Therapeutics, Inc. will host an Investor Conference Call on January 28, 2026, to discuss preliminary unaudited full year 2025 revenue results, updated financial guidance for 2026-2028, and a business update [1] Group 1: Company Overview - Halozyme is a biopharmaceutical company focused on improving patient experiences and outcomes through innovative drug delivery solutions [3] - The company is known for its ENHANZE drug delivery technology, which facilitates subcutaneous delivery of injected drugs, impacting over one million patients through ten commercialized products across more than 100 global markets [3] - Halozyme has partnerships with leading pharmaceutical companies, including Roche, Takeda, Pfizer, and others, to utilize its drug delivery technology [3] Group 2: Product Development - Halozyme is developing Hypercon™, a microparticle technology aimed at enhancing drug concentration and reducing injection volume, which broadens the scope of therapeutics for subcutaneous delivery [4] - The company also focuses on drug-device combination products using advanced auto-injector technologies to improve patient comfort and adherence [5] - Halozyme has two proprietary commercial products, Hylenex and XYOSTED, along with partnered commercial products and ongoing development programs with Teva Pharmaceuticals and McDermott Laboratories Limited [5] Group 3: Corporate Information - Halozyme is headquartered in San Diego, California, with additional offices in Ewing, New Jersey; Minnetonka, Minnesota; and Boston, Massachusetts [6]

Core Insights - Lexaria Bioscience Corp. has made significant advancements in oral drug delivery technology, particularly in the GLP-1 sector, utilizing its proprietary DehydraTECH™ (DHT) technology [3][11][60] - The company reported a substantial increase in the market for GLP-1 drugs, with worldwide revenues rising from $34.4 billion in 2024 to $51.9 billion in 2025, marking a 51% year-over-year growth [8] - Lexaria's DHT technology has shown promising results in reducing adverse events (AEs) associated with GLP-1 drugs, which are primarily injectable, thus presenting a significant market opportunity [12][14][58] 2025 Highlights - In 2025, Lexaria focused its resources on studying its DHT technology with the three leading GLP-1 drugs: semaglutide, tirzepatide, and liraglutide [5][6] - The company completed its first Phase 1b registrational study in Australia, achieving a gross total of $9.5 million through three equity raises [6][49] - Lexaria's DHT technology demonstrated positive results across all R&D studies conducted in 2025, including significant reductions in AEs [6][58] Market Dynamics - The GLP-1 drug market is becoming increasingly competitive, with new companies and products emerging regularly, and existing drugs expanding their indications beyond diabetes and weight loss [9] - Despite the overall market growth, the orally-delivered segment of GLP-1 drugs has seen limited revenue growth, with only 5% of total revenues from oral products in 2025 [10] Research and Development - Lexaria's studies in 2025 included Human Pilot Studies that showed DHT-processed drugs had reduced AEs compared to their injectable counterparts, with notable reductions in gastrointestinal issues [18][29] - The company plans to leverage findings from its 2025 studies to design new R&D work in 2026, focusing on improving oral GLP-1 formulations [34][36] Collaboration and Business Development - Lexaria has extended its Material Transfer Agreement (MTA) with a pharmaceutical partner to evaluate DHT technology, allowing for continued collaboration and strategic planning [41][43] - The company is actively pursuing discussions with various pharmaceutical companies for potential partnerships, not only in the GLP-1 sector but also in other therapeutic areas [46][48] Financial Overview - Lexaria raised $9.5 million in 2025, successfully capitalizing on favorable market conditions to fund its R&D activities through 2026 [49][50] - The company has sufficient funding to support its operations and marketing campaigns in 2026, despite previous stock price weaknesses [55][56] Future Outlook - Lexaria aims to develop the world's first oral version of liraglutide using DHT and is exploring additional R&D opportunities outside the GLP-1 sector [63][40] - The company is committed to advancing its DHT technology and believes it is closer to a commercial breakthrough than ever before [60][61]

Core Insights - Halozyme Therapeutics has entered into a global collaboration and exclusive license agreement with Takeda for the use of its ENHANZE drug delivery technology with vedolizumab, marketed as ENTYVIO [1][2] - The collaboration aims to enhance patient experience by providing flexible treatment options for those with inflammatory bowel disease (IBD), specifically Crohn's disease and ulcerative colitis [2][3] Company Overview - Halozyme is a biopharmaceutical company focused on innovative solutions to improve patient experiences and outcomes, particularly through its ENHANZE drug delivery technology, which utilizes the proprietary enzyme rHuPH20 [5] - The ENHANZE technology has been validated commercially, impacting over one million patients through ten products across more than 100 global markets [5] - Halozyme is also developing Hyperconâ™, a microparticle technology aimed at reducing injection volume while expanding the range of therapeutics that can be delivered subcutaneously [6] Industry Context - Crohn's disease and ulcerative colitis are significant forms of IBD, with an estimated 10 million people expected to be living with IBD globally within the next decade, indicating a growing healthcare burden [3] - Vedolizumab (ENTYVIO) is a biologic therapy approved for both intravenous and subcutaneous administration for adults with moderately to severely active IBD [4]

Core Insights - Halozyme Therapeutics and Skye Bioscience have entered a non-exclusive global collaboration to develop a subcutaneous formulation of nimacimab for obesity treatment, utilizing Halozyme's ENHANZE drug delivery technology [1][2] - The collaboration aims to evaluate higher doses of nimacimab through larger injection volumes, with Skye planning to initiate a Phase 2b clinical trial in mid-2026 [3] Group 1: Collaboration Details - Skye has licensed Halozyme's ENHANZE technology to support the development and commercialization of nimacimab, which is intended to enhance treatment options for obesity [1][2] - Skye will make milestone payments based on the achievement of specific development and commercialization events, while Halozyme will receive mid-single digit royalties on net sales of nimacimab for at least 10 years [2] Group 2: Market Potential and Strategy - The collaboration expands Halozyme's ENHANZE technology into the obesity market, which is identified as having significant long-term potential [2] - Halozyme's strategy focuses on driving sustainable royalty growth through new partnerships and innovations, reinforcing the scalability of ENHANZE across various therapeutic indications [2] Group 3: Clinical Development Plans - Skye plans to assess the combination of nimacimab with a GLP-1 receptor agonist in the upcoming Phase 2b clinical trial, which will evaluate multiple dose-ranging strategies [3][9] Group 4: Company Background - Halozyme is a biopharmaceutical company that develops solutions to improve patient experiences and outcomes, with a focus on drug delivery technologies [4][5] - The ENHANZE technology has been validated commercially and is licensed to numerous leading pharmaceutical companies, enhancing its market presence [5] Group 5: Future Innovations - Halozyme is also developing Hypercon™, a microparticle technology aimed at reducing injection volumes while expanding the scope of therapeutics that can be delivered subcutaneously [6] - The company is engaged in developing drug-device combination products to improve patient comfort and adherence [7]